CL2014003241A1 - Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. - Google Patents
Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.Info
- Publication number
- CL2014003241A1 CL2014003241A1 CL2014003241A CL2014003241A CL2014003241A1 CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1 CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1
- Authority
- CL
- Chile
- Prior art keywords
- lpar
- antagonists
- pulmonary fibrosis
- acid receptor
- lysophosphatidic acid
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000005069 pulmonary fibrosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661953P | 2012-06-20 | 2012-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003241A1 true CL2014003241A1 (es) | 2015-03-20 |
Family
ID=48628669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003241A CL2014003241A1 (es) | 2012-06-20 | 2014-11-28 | Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150133512A1 (enExample) |
| EP (1) | EP2864301A1 (enExample) |
| JP (1) | JP2015520203A (enExample) |
| KR (1) | KR20150011389A (enExample) |
| CN (1) | CN104395299A (enExample) |
| AU (1) | AU2013279513A1 (enExample) |
| BR (1) | BR112014030674A2 (enExample) |
| CA (1) | CA2869564A1 (enExample) |
| CL (1) | CL2014003241A1 (enExample) |
| CO (1) | CO7131357A2 (enExample) |
| EA (1) | EA201492281A1 (enExample) |
| HK (1) | HK1206339A1 (enExample) |
| IL (1) | IL236087A0 (enExample) |
| IN (1) | IN2014DN09352A (enExample) |
| MA (1) | MA37762B1 (enExample) |
| MX (1) | MX2014014711A (enExample) |
| PE (1) | PE20142305A1 (enExample) |
| PH (1) | PH12014502363A1 (enExample) |
| SG (1) | SG11201407228PA (enExample) |
| UA (1) | UA110310C2 (enExample) |
| WO (1) | WO2013189865A1 (enExample) |
| ZA (1) | ZA201408167B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2844982A1 (en) | 2011-08-15 | 2013-02-21 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| CN106458964B (zh) | 2014-06-27 | 2019-11-22 | 宇部兴产株式会社 | 卤素取代杂环化合物的盐 |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
| CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
| KR20200100713A (ko) | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| CN112041029B (zh) | 2017-12-19 | 2025-01-24 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑唑类 |
| SG11202005701VA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| WO2019126099A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| WO2019126093A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| ES2943661T3 (es) | 2017-12-19 | 2023-06-15 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| KR102725744B1 (ko) | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| KR102950123B1 (ko) | 2018-09-18 | 2026-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로펜틸 산 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| JP7591066B2 (ja) | 2020-06-03 | 2024-11-27 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| JP7709612B2 (ja) | 2021-12-08 | 2025-07-16 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
| US20240343695A1 (en) * | 2023-03-06 | 2024-10-17 | Lakehead University | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| CN103347510B (zh) * | 2010-12-07 | 2015-11-25 | 艾米拉医药股份有限公司 | 溶血磷脂酸受体拮抗剂及其在治疗纤维化中的用途 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| CA2844982A1 (en) * | 2011-08-15 | 2013-02-21 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| HK1206342A1 (en) * | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | N-alkyltriazole compounds as lpar antagonists |
-
2013
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/en not_active Ceased
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
- 2013-06-17 CA CA2869564A patent/CA2869564A1/en not_active Abandoned
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/en not_active Withdrawn
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Ceased
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 HK HK15106924.1A patent/HK1206339A1/xx unknown
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA110310C2 (uk) | 2015-12-10 |
| CN104395299A (zh) | 2015-03-04 |
| AU2013279513A1 (en) | 2014-10-16 |
| CO7131357A2 (es) | 2014-12-01 |
| MX2014014711A (es) | 2015-03-04 |
| KR20150011389A (ko) | 2015-01-30 |
| WO2013189865A1 (en) | 2013-12-27 |
| JP2015520203A (ja) | 2015-07-16 |
| MA37762B1 (fr) | 2018-04-30 |
| EP2864301A1 (en) | 2015-04-29 |
| HK1206339A1 (en) | 2016-01-08 |
| EA201492281A1 (ru) | 2015-04-30 |
| PE20142305A1 (es) | 2015-01-16 |
| CA2869564A1 (en) | 2013-12-27 |
| ZA201408167B (en) | 2015-12-23 |
| BR112014030674A2 (pt) | 2017-06-27 |
| US20150133512A1 (en) | 2015-05-14 |
| PH12014502363A1 (en) | 2015-01-12 |
| MA37762A1 (fr) | 2017-07-31 |
| IN2014DN09352A (enExample) | 2015-07-17 |
| SG11201407228PA (en) | 2014-12-30 |
| IL236087A0 (en) | 2015-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014003243A1 (es) | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. | |
| IL277652A (en) | Stable aqueous formulations of adlimumab | |
| CL2014003242A1 (es) | Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar. | |
| DK2882850T3 (da) | System for preparation of adipose-derived stem cells | |
| IL230913A0 (en) | Lysophosphatidic acid receptor antagonists | |
| PL3862010T3 (pl) | Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała | |
| IL226491A0 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | |
| IL236087A0 (en) | n–aryltriazole compounds as lpar antagonists | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| PL2928870T3 (pl) | Ligandy receptora neurotensyny | |
| HUE038128T2 (hu) | Dexmedetomidin premix készítmény | |
| IL236688A0 (en) | Beta amino acid derivatives as integrin antagonists | |
| CR20140263A (es) | Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
| EP2925325A4 (en) | STABILIZED FORMULATION OF PEMETREXED | |
| CO6950497A2 (es) | Compuestos de 1,2,5-oxadiazol sustituidos y su uso como herbicidas | |
| BR112013012452A2 (pt) | uso de dispersões aquosas como primers | |
| CL2015001399A1 (es) | Composiciones detergentes acuosas de estructura polimérica. | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| ZA201600753B (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| PL2836580T3 (pl) | Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu | |
| CR20140343A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| BR112014010153A2 (pt) | formulação esporicida, lenço e lenço umedecido | |
| BR112013009640A2 (pt) | derivados de tetrahidroquinolina usados como ativadores de ampk | |
| ZA201500979B (en) | Electrochemical generation of chlorinated urea derivatives | |
| EP2939672A4 (en) | PROMOTER OF IGF-1 PRODUCTION |